Clinical Trial Update: Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial from Orano Med LLC is evaluating targeted alpha-emitter therapy for neuroendocrine tumors in PRRT-naïve and previously treated patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Snippet

Sponsor: Orano Med LLC | Conditions: Neuroendocrine Tumors | Phase 2 | Status: ACTIVE_NOT_RECRUITING